Sareum Collaborates with Infinity Pharmaceuticals
News Sep 22, 2005
Sareum Holdings plc has announced that it has entered into a collaborative agreement with Infinity Pharmaceuticals, Inc. to provide protein structure determination capabilities to accelerate Infinity’s drug discovery research.
Sareum will utilise its skills in high throughput protein expression, purification and structure determination to illustrate the precise nature of how Infinity’s potential drug candidates interact with target receptor proteins.
This detailed structural information will assist Infinity’s scientists in their search for improved cancer therapeutics by driving lead optimization results and providing co-complex structures for Infinity’s compounds.
“We are delighted that Infinity has chosen Sareum as their partner in protein structure determination,” commented Dr. Tim Mitchell, Sareum’s Chief Executive Officer.
“This is our first protein structure determination collaboration in the United States and a significant first step into a very important market.”
“We look forward to successful delivery of this project to Infinity and to closing additional partnerships such as this.”
Dr. Julian Adams, Infinity’s Chief Scientific Officer remarked, “Sareum’s protein structure determination technologies and expertise will enhance Infinity’s ability to design better, more robust molecules for the creation of new cancer treatments.”
“This partnership further illustrates Infinity’s commitment to accelerate the discovery of novel therapeutics for patients suffering from cancer.”
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.READ MORE
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE